Chronic Inflammation in Asthma: Looking Beyond the Th2 Cell

ABSTRACT Asthma is a common chronic inflammatory disease of the airways. A substantial number of patients present with severe and therapy‐resistant asthma, for which the underlying biological mechanisms remain poorly understood. In most asthma patients, airway inflammation is characterized by chronic activation of type 2 immunity. CD4 + T helper 2 (Th2) cells are the canonical producers of the cytokines that fuel type 2 inflammation: interleukin (IL)‐4, IL‐5, IL‐9, and IL‐13. However, more recent findings have shown that other lymphocyte subsets, in particular group 2 innate lymphoid cells (ILC2s) and type 2 CD8 + cytotoxic T (Tc2) cells, can also produce large amounts of type 2 cytokines. Importantly, a substantial number of severe therapy‐resistant asthma patients present with chronic type 2 inflammation, despite the high sensitivity of Th2 cells for suppression by corticosteroids—the mainstay drugs for asthma. Emerging evidence indicates that ILC2s and Tc2 cells are more abundant in severe asthma patients and can adopt corticosteroid‐resistance states. Moreover, many severe asthma patients do not present with overt type 2 airway inflammation, implicating non‐type 2 immunity as a driver of disease. In this review, we will discuss asthma pathophysiology and focus on the roles played by ILC2s, Tc2 cells, and non‐type 2 lymphocytes, placing special emphasis on severe disease forms.